Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Eloxx Pharmaceuticals Inc (ELOX) has shared an update.
Eloxx Pharmaceuticals has initiated a stock option repricing for their CEO’s eligible options under the 2018 Equity Incentive Plan, reducing the exercise price to $0.90, aligning with the closing stock price on March 25, 2024. This move affects both vested and unvested options, significantly lowering the weighted average exercise price from $37.47 for nearly 200,000 shares owned by CEO Sumit Aggarwal, potentially making it more attractive for investment and retention purposes.
See more insights into ELOX stock on TipRanks’ Stock Analysis page.
